Pfizer announced a second collaboration agreement with Arvinas to develop and commercialize the Connecticut-based company’s PROTAC estrogen receptor protein degrader.
Thermo Fisher Scientific launched a new collaborative unit that aims to standardize the metabolomics community’s efforts as the company engages in more large-scale cohort studies and clinical research.
Global pharmaceutical operations and technology company Biogen partnered with Chinese commercial-stage biopharmaceutical firm InnoCare Pharma to develop a treatment for multiple sclerosis.
ObvioHealth Raises $31 Million, Adds Two Strategic Partners to Bolster Capabilities and Drive Growth Globally NEW YORK, July 1, 2021 /PRNewswire/ — ObvioHealth, a global Virtual Research Organization (VRO), announces it has raised $31 million in its latest round of financing. The round was led by two new partners: Dedalus Group, an international healthcare IT and […]
Arrowhead Pharmaceuticals and Horizon Therapeutics announced a research and development collaboration to advance an RNA interference (RNAi) therapeutic for uncontrolled gout.
Bristol Myers Squibb and Eisai forged a strategic collaboration that could be worth nearly $2.5 billion to jointly develop MORAb-202, an antibody drug conjugate (ADC) to be used against certain solid tumors across several different cancer types.
Across the pharmaceutical industry, forging collaborations are a key tool to bringing new medications through the clinic and to market. This week, multiple companies have partnered in attempts to bring forth new therapies. BioSpace took a look at some of these announcements.
The U.S. Food and Drug Administration granted approval to Myfembree, Myovant Sciences and Pfizer’s once-daily treatment for heavy menstrual bleeding associated with uterine fibroids in premenopausal women. Patients receiving the therapy under the newly approved indication can take the medicine for up to 24 months.
CytoReason and Ferring Pharmaceuticals announced a collaboration that pairs CytoReason’s artificial intelligence (AI)-based computational model of the human body with Ferring’s expertise in inflammatory bowel disease (IBD). The purpose is to develop cell-based disease models to accelerate drug discovery and reduce development costs.
One day after Bristol Myers Squibb announced a licensing deal with Agenus with an upside potential of $1.56 billion, BMS inked a collaboration agreement with Artificial Intelligence (AI)-focused biopharma company Exscientia that could hit $1.2 billion.
